Importance Worldwide, the burden of heart failure has increased to an estimated 23 million
people, and approximately 50% of cases are HF with reduced ejection fraction (HFrEF) …

Carbohydrates are fundamental molecules involved in nearly all aspects of lives, such as
being involved in formating the genetic and energy materials, supporting the structure of …

Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …

The management of type 2 diabetes mellitus (T2DM) is becoming increasingly complex.
Sodium–glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic …

Background In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2
(SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose …

Abstract Sodium–glucose cotransporter (SGLT) 2 inhibitors have been demonstrated to
reduce cardiovascular events, particularly heart failure, in cardiovascular outcome trials …

Heart failure and related morbidity and mortality are increasing at an alarming rate, in large
part, because of increases in aging, obesity, and diabetes mellitus. The clinical outcomes …

Background: Effective diuretic regimens using loop diuretics in patients with acute
decompensated heart failure are often limited by the development of worsening kidney …

Background: SGLT2 (sodium-glucose cotransporter-2) inhibitors improve heart failure–
associated outcomes in patients with type 2 diabetes. In patients with heart failure, SGLT2 …

Background: SGLT2 (sodium/glucose cotransporter 2) inhibitors exert robust
cardioprotective effects against heart failure in patients with diabetes, and there is intense …